Sign In
Buy HCM
$9.99
-0.290 (-2.82%)
At Close: Jun 22, 2026
Paycom: Initiating Buy On Strong Growth Tailwind And BETI Pricing Power
10:34pm, Monday, 20'th May 2024
Paycom is recommended as a buy due to its long-term growth potential and strong value proposition with its BETI product. The global HCM software industry is expected to grow, providing opportunities f
Applications Software Technology收购Symatrix，以加速甲骨文云服务的全球扩张
11:11am, Monday, 20'th May 2024
伊利诺伊州莱尔--(BUSINESS WIRE)--(美国商业资讯)-- 领先的数字化转型解决方案供应商Applications Software Technology (AST) 今天宣布签订收购英国领先IT和甲骨文服
Applications Software Technology adquiere Symatrix con el objetivo de acelerar su expansión global en servicios de Oracle Cloud
11:08am, Monday, 20'th May 2024
LISLE, Ill.--(BUSINESS WIRE)--Applications Software Technology (AST), proveedor líder de soluciones para la transformación digital, anuncia que ha firmado un acuerdo definitivo para la adquisición
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
10:00am, Friday, 17'th May 2024
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces:-
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from
— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED'
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a regis
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
04:30am, Wednesday, 08'th May 2024
HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM, HKEX: 13) today announces tha
HUTCHMED (HCM) Upgraded to Buy: Here's What You Should Know
01:00pm, Tuesday, 30'th Apr 2024
HUTCHMED (HCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?
10:56am, Tuesday, 30'th Apr 2024
The mean of analysts' price targets for HUTCHMED (HCM) points to a 38.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
08:30am, Friday, 26'th Apr 2024
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade —
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
04:30am, Friday, 05'th Apr 2024
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data f
— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 —
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients —
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 22, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the r
